Skip to main content
. Author manuscript; available in PMC: 2017 Sep 15.
Published in final edited form as: Clin Cancer Res. 2016 Apr 27;22(18):4612–4622. doi: 10.1158/1078-0432.CCR-15-2703

Figure 5. Progression-free survival in metastatic CRC patients treated with CAP (solid lines) or CAPIRI (dashed lines) as a function of WRN promoter region methylation.

Figure 5

PFS is shown for CRCs with unmethylated (panel A) or methylated (panel B) WRN promoter regions. HR = Hazard Ratio (CAPIRI vs CAP).